Ropivacaine: An Option for Acute Pain Analgesia and Local Anesthesia

Abstract

Ropivacaine is an amide-type local anesthetic developed as a pure S-enantiomer. It acts by reversibly inhibiting voltage-gated sodium channels in Aδ and C nociceptive nerve fibers. Due to its lower lipid solubility compared to bupivacaine, ropivacaine exhibits limited penetration into large myelinated motor fibers, resulting in a more selective sensory blockade. Its onset of action ranges from 3 to 15 minutes. While its analgesic potency is similar to that of bupivacaine, its motor blocking potency is approximately 80%. This characteristic provides a significant clinical advantage by facilitating faster motor recovery in postoperative patients. Its therapeutic indications include both surgical anesthesia and acute pain management in adult and pediatric populations. Compared to bupivacaine, ropivacaine exhibits a significantly greater threshold for central nervous system and cardiovascular toxicity because of its pure enantiomeric structure and less lipophilicity. Furthermore, it demonstrates a favorable safety profile in pregnant and lactating women. The incidence of acute IgE-mediated hypersensitivity reactions is very low, accounting for less than 1%. However, caution for potential cross-reactivity is required in patients with a documented history of hypersensitivity to other amide-type local anesthetics. Ropivacaine is extensively metabolized in the liver primarily via CYP1A2 and CYP3A4 enzymes. Consequently, drug-drug interactions with concurrent use of inhibitors of these enzymes, such as fluvoxamine and ketoconazole, should be closely monitored. In contemporary clinical practice, ropivacaine represents a preferred alternative for regional anesthesia and pain management due to its high efficacy, favorable safety profile, and low allergenicity.